Ionis Pharmaceuticals, Inc.(IONS)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
IONS | 7.54 B | - | -40.70% | -64.66% | -$3.62 | -105.50% | 4.98x | 0.00% | $86.74 | $42.08 |
MRNA | 96.65 B | - | 2.10% | -141.43% | -$8.73 | -39.00% | 0.19x | 0.00% | $242.29 | $22.28 |
EXEL | 15.95 B | 19.22x | 10.60% | 35.33% | $3.35 | 44.39% | 0.09x | 0.00% | $63.31 | $33.76 |
NBIX | 14.43 B | 20.55x | 39.50% | 20.91% | $6.91 | 22.09% | 0.13x | 0.00% | $186.12 | $122.14 |
BBIO | 13.21 B | - | 120.40% | -97.03% | -$3.77 | - | - | 0.00% | $93.42 | $52.75 |
Peer Valuation & Performance Analysis
Peer group analysis for Ionis Pharmaceuticals, Inc. (IONS) compared to its primary competitors (including MRNA, EXEL, NBIX) reveals distinct metrics. IONS trades at a valuation discount relative to its competitors, with a P/E ratio of -12.5x versus the peer average of -1.5x (representing a 754% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, IONS's revenue growth of -40.7% lags behind the peer average of 43.1%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of -64.7% is below the peer average of -45.6%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• IONS ranks #0 in P/E ratio, #5 in revenue growth, and #3 in profit margins
• Average ranking: #3 - 📊 Solid financials relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-20 | $44.45 | $45.48 | $44.01 | $45.40 | 2,486,457 | +2.30% |
| 2026-10-19 | $43.33 | $44.54 | $43.00 | $44.38 | 3,098,900 | +3.35% |
| 2026-10-16 | $44.53 | $44.65 | $42.80 | $42.94 | 1,674,800 | -2.67% |
| 2026-10-15 | $43.58 | $44.71 | $43.42 | $44.12 | 2,484,800 | +3.33% |
| 2026-10-14 | $42.22 | $43.47 | $42.08 | $42.70 | 2,027,200 | +0.76% |
| 2026-10-13 | $43.55 | $43.58 | $42.36 | $42.38 | 2,977,600 | -2.95% |
| 2026-10-12 | $45.37 | $45.46 | $43.62 | $43.67 | 1,950,400 | -3.56% |
| 2026-10-09 | $43.21 | $45.72 | $43.12 | $45.28 | 4,862,000 | +4.57% |
| 2026-10-08 | $43.76 | $44.19 | $42.79 | $43.30 | 3,349,200 | -1.95% |
| 2026-10-07 | $43.75 | $44.26 | $43.53 | $44.16 | 2,943,600 | +0.36% |
| 2026-10-06 | $44.19 | $44.67 | $43.17 | $44.00 | 2,192,600 | +1.15% |
| 2026-10-05 | $43.75 | $43.96 | $42.63 | $43.50 | 2,870,600 | -0.09% |
| 2026-10-02 | $44.17 | $44.17 | $43.24 | $43.54 | 2,312,000 | -1.05% |
| 2026-10-01 | $44.63 | $45.95 | $43.96 | $44.00 | 2,030,200 | -1.46% |
| 2026-09-30 | $46.07 | $46.25 | $44.60 | $44.65 | 2,630,200 | -2.70% |
Explore More Analysis for IONS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.